Hematological Neoplasms
Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy #MultipleMyeloma #CAR_Therapy #CancerTreatment #HRMM #MM #RRMM #CART In the fight against multiple myeloma (MM), the last few decades have seen significant advancements, yet the disease remains notoriously difficult to cure, particularly in patients with relapsed/refractory multiple myeloma (RRMM). Read More
On July 24, 2020, the FDA approved Tecatus for the treatment of relapsed/refractory mantle cell lymphoma (MCL) in adult patients, It is the first and only CAR-T therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) in adult patients.
Tecartus (brexucabtagene autoleucel), developed by Kite Pharma (now part of Gilead Sciences), is one such therapy that has gained significant attention for its efficacy in treating certain types of lymphoma and leukemia.
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After receiving treatments at the best hospital in Thailand, including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation. The disease rapidly relapsed. Local doctors informed Read More
On July 24, 2020, the US Food and Drug Administration (FDA) granted accelerated approval to Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Subsequently, on October 1, 2021, the FDA expanded the approval of Tecartus to include the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).